表紙
市場調査レポート

医薬品のADMET (薬物動態毒性) 検査:世界市場予測 2015-2025年

Pharma Admet Testing: World Industry and Market Prospects 2015-2025

発行 Visiongain Ltd 商品コード 341090
出版日 ページ情報 英文 156 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=139.44円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品のADMET (薬物動態毒性) 検査:世界市場予測 2015-2025年 Pharma Admet Testing: World Industry and Market Prospects 2015-2025
出版日: 2015年10月01日 ページ情報: 英文 156 Pages
概要

ADMET (薬物動態毒性) 検査は、薬剤開発の欠くことのできない部分です。ADMET検査市場は2014年に58億米ドル規模となり、体内検査収益の大部分に貢献しました。

当レポートでは、世界におけるADMET (吸収、分布、代謝、排泄、毒性) 検査市場の現状と見通しについて調査分析し、成長促進因子・阻害因子、市場全体・2次市場・主要国市場における収益予測、主要企業の評価、専門家へのインタビュー、および今後の見通しなどをまとめています。

第1章 調査概要

第2章 ADMET検査のイントロダクション

  • ADMET検査とは?
  • 生物学的類似性におけるADMET検査の役割
  • 試験設計・実行

第3章 ADMET検査:世界市場

  • 医薬品のR&D支出:フェーズ別
    • 経済がADMET検査市場に及ぼす影響
    • 大手製薬企業はCROの主要クライアント
  • ADMET検査市場
    • 成長促進因子
    • 全体的な収益予測

第4章 ADMET検査:セグメント別の収益

  • 最も収益の大きい部門は?
  • 10年間の予測ADMET検査の需要拡大
  • 体外ADMET検査
    • 促進因子・阻害因子
  • 体内ADMET検査
  • コンピューターADMET検査

第5章 ADMET検査:主な先進市場

  • ADMET検査の主要国市場
  • ADMET検査:主要国市場の予測
  • 薬剤開発の目的地としての北米
    • 米国:ADMET検査の最大市場
    • 米国:ADMET検査収益予測
  • EU5カ国におけるADMET検査の展望
    • EUにおける臨床試験ルールの書き換え
    • EU5カ国:市場全体・主要国市場の予測
    • ドイツ:市場予測
    • 英国
    • フランス:市場予測
    • イタリア:市場予測
    • スペイン:市場予測
  • 日本は近隣の新興市場との競合に見舞われる
    • 日本におけるADMET検査の成長

第6章 ADMET検査:主な新興市場

  • ADMET検査の主な新興市場
    • 新興市場でADMET検査を実施するメリット
    • 新興市場で非臨床研究を実施する課題
  • 新興ADMET検査市場の力強い成長予測
  • アジア太平洋におけるADMET:新興市場の見通し
    • 中国は2025年においてADMET検査の最大の新興市場となる見込み
    • 臨床試験拠点としてのインド
    • 韓国
  • ロシア
    • 薬剤開発需要の変化い
    • ロシアのADMET検査市場予測
  • ブラジル:ラテンアメリカにおける最大の薬剤開発市場
    • ブラジルのADMET検査市場予測

第7章 ADMET検査産業における主要企業

  • Agilent Technologies, Inc.
  • Dassault Systemes: Accelrys を買収し BIOVIAを設立
  • Cyprotex
  • Bio-Rad Laboratories, Inc.
  • Quintiles
  • Increasing Asian Regional Reach
  • Charles River Laboratories は前臨床サービスの専門
  • Promega Corporation
  • Merck KGaA による Sigma Aldrich の買収

第8章 ADMET検査市場:産業動向

  • 強みと弱み
  • 機会と脅威
  • STEP分析
  • より効率的な検査のための技術改善
  • ADMET検査のための経済上の検討事項
  • ADMET検査に影響を及ぼす政治・規制の発展

第9章 調査インタビュー

第10章 結論

図表

目次
Product Code: PHA0069

ADMET Products and Services - Your Guide to Trends and Revenue Potentials

The pharma ADMET testing market gains much interest from pharmaceutical companies as they look to implement more-predictive ADMET testing. That finding and many others appear in a new report by visiongain.

Absorption, distribution, metabolism, excretion and toxicology (ADMET) testing is an integral part of drug development. Visiongain estimates the ADMET testing market was valued at $5.80bn in 2014, with the majority of revenues being attributed to in vitro testing.

Our new report gives you 51 tables, 48 charts and three interviews. Discover the most lucrative areas in that industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions for those pharma R&D technologies. There is much opportunity in that fast moving market.

image1

image2

Forecasts from 2015-2025 and other analyses show you commercial prospects

Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments. Commercial drivers and restraints for each submarket are also provided, as are revenue forecasts to 2025.

  • In vitro ADMET testing
  • In vivo ADMET applications
  • In silico ADMET uses.

Our new study predicts the pharma ADMET testing market will expand throughout the forecast period, 2015 to 2025, driven by increased demand for that screening and advances in technology enhancing the reliability and predictive capabilities of those assays.

image3

image4

Leading companies and potential for market growth

Overall revenue for the pharma ADMET testing market will reach $10.51bn in 2019, our work forecasts. We predict strong revenue growth through to 2025, as drug developers select stronger product candidates for development, using ADMET technology.

Our work also analyses prominent companies in that market. See visiongain's analysis of leading companies, including these:

  • Agilent Technologies
  • BIOVIA
  • Cyprotex
  • Bio-Rad Laboratories
  • Quintiles
  • CMIC
  • Charles River Laboratories
  • WuXi PharmaTech
  • Promega Corporation
  • Sigma-Aldrich.

A company profile gives you the following information where available:

  • Recent historical revenues
  • Discussion of a company's activities, technologies and outlook
  • Brief assessment of the company's ADMET strategy.

With that information you will assess competitors' capabilities, progress, and commercial prospects, helping you stay ahead and benefit your reputation for insight.

image5

image6

National markets for those drug development technologies

Our study shows you prospects for ADMET sales in developed and developing countries. You will see individual revenue forecasts to 2025 for 12 countries:

  • United States
  • Japan
  • Germany, France, United Kingdom, Italy and Spain (EU5)
  • Brazil, Russia, India and China (BRIC)
  • South Korea.

With our analysis you will investigate regions with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

What forces affect the pharma ADMET testing industry?

Our new report discusses issues and events affecting the pharmaceutical ADMET testing industry and market. You will find discussions, including qualitative analyses:

  • Rising demand for early ADMET testing
  • Developments in that drug screening technology.

You will see discussions of technological, commercial, and economic issues, with emphasis on the competitive landscape and business outlooks. Discover what the future holds.

How Pharma ADMET Testing: World Industry and Market Prospects 2015-2025 helps

In particular, our new investigation gives the following knowledge to benefit your work:

  • Revenue forecasts to 2025 for the pharma ADMET testing market - discover that industry's commercial prospects, finding what revenues and growth are possible
  • Revenue forecasts to 2025 for three submarkets - explore sales potentials of in vitro, in vivo and in silico testing
  • Revenue forecasts to 2025 for 12 leading national markets - US, EU5 (Germany, France, UK, Italy and Spain), Japan, Brazil, Russia, India, China and South Korea
  • Assessment of leading companies - assess competitors, exploring their product and service portfolios, strategic developments and commercial outlooks
  • Exclusive interviews with three companies - gain opinions from MultiCASE Inc., Optivia Biotechnology and Takara Bio Europe AB, seeing what participants say and do
  • Discussion of what stimulates and restrains companies and the market - examine forces affecting those technologies and their providers
  • Prospects for established firms and those seeking to enter the industry - discover what the future holds, helping you stay ahead in knowledge.

There you will find quantitative and qualitative analyses with independent predictions. That way you will receive information that only our report contains, staying informed on business intelligence.

Data and discussions found nowhere else, helping your research, analyses and decisions

With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's new study is for everybody needing analyses of the pharma ADMET testing market and that industry's leading companies. There you will find data, trends and predictions. Stay ahead by getting that report here now.

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Market for ADMET Testing
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analysis
  • 1.5 Who Is This Study For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Some Associated Reports
  • 1.9 About Visiongain

2. An Introduction to ADMET Testing

  • 2.1 What Is ADMET Testing?
    • 2.1.1 Absorption
    • 2.1.2 Distribution
    • 2.1.3 Metabolism
    • 2.1.3.1 MIST Guidelines
    • 2.1.4 Excretion
    • 2.1.5 Toxicology
  • 2.2 The Role of ADMET Testing in Biosimilarity
  • 2.3 Trial Design and Execution
    • 2.3.1 Phases of Drug Development
      • 2.3.1.1 Phase 0 Trials: Establishing Pharmacodynamic and Pharmacokinetic Properties
      • 2.3.1.2 Phase I Trials: First-In-Human Studies
      • 2.3.1.3 Phase II Trials: Proof-Of-Concept
      • 2.3.1.4 Phase III Trials: Preparing for Approval Applications
      • 2.3.1.5 Post-Marketing Studies
    • 2.3.2 Reducing Attrition Rates in Drug Development through Predictive ADMET
    • 2.3.3 Benefits of Outsourcing

3. ADMET Testing: World Market 2015-2025

  • 3.1 Pharma R&D Expenditures by Phase, 2014
    • 3.1.1 The Impact of the Economy on the ADMET Testing Market, 2008-2014
    • 3.1.2 Big Pharma Companies Are the Leading Clients for CROs
  • 3.2 The ADMET Testing Market 2015-2025
    • 3.2.1 What Will Drive Growth in ADMET Testing 2015-2025?
    • 3.2.2 The ADMET Testing Market: Overall Revenue Forecast 2015-2025

4. ADMET Testing: Revenue by Segment 2015-2025

  • 4.1 Which Market Sector Will Account for the Most Revenue from 2015-2025?
  • 4.2 Rising Demand for Predictive ADMET Testing throughout the Decade
  • 4.3 In Vitro ADMET Testing Market
    • 4.3.1 In Vitro ADMET Testing: Drivers and Restraints
  • 4.4 In Vivo ADMET Testing Market
    • 4.4.1 In Vivo ADMET Testing: Drivers and Restraints
  • 4.5 In Silico ADMET Testing
    • 4.5.1 In Silico ADMET Testing: Drivers and Restraints

5. ADMET Testing: Leading Developed Markets 2015-2025

  • 5.1 Leading National Markets for ADMET Testing 2014
  • 5.2 ADMET Testing: Leading National Market Forecasts 2015-2025
  • 5.3 North America as a Destination for Drug Development
    • 5.3.1 The US: The Largest National Market for ADMET Testing 2015-2025
      • 5.3.1.1 Government Programs to Improve ADMET in the US
    • 5.3.2 The US: ADMET Testing Revenue Forecast 2015-2025
  • 5.4 The Outlook for ADMET Testing in the EU5 2015-2025
    • 5.4.1 Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation
    • 5.4.2 EU5: Overall Market and Leading National Market Forecasts 2015-2025
    • 5.4.3 Germany: Market Forecast 2015-2025
    • 5.4.4 The UK
      • 5.4.4.1 Overcoming Challenges in UK Clinical Trials
      • 5.4.4.2 UK ADMET Testing Market Forecast 2015-2025
    • 5.4.5 France: Market Forecast 2015-2025
    • 5.4.6 Italy: Market Forecast 2015-2025
    • 5.4.7 Spain: Market Forecast 2015-2025
  • 5.5 Japan Is Being Challenged by Neighbouring Emerging Markets
    • 5.5.1 Growth for ADMET Testing in Japan 2015-2025

6. ADMET: Leading Emerging Markets 2015-2025

  • 6.1 Leading Emerging Markets for ADMET Testing 2014
    • 6.1.1 Benefits of Conducting ADMET Testing in Emerging Markets
    • 6.1.2 Challenges of Conducting Non-Clinical Studies in Emerging Markets
  • 6.2 Strong Growth Forecast for Emerging ADMET Testing Markets 2015-2025
  • 6.3 ADMET in Asia Pacific: An Emerging Market Perspective
    • 6.3.1 China Will be the Largest Emerging Market for ADMET Testing in 2025
      • 6.3.1.1 CRO Investments and Partnerships in China
      • 6.3.1.2 Chinese ADMET Testing Market Forecast 2015-2025
    • 6.3.2 India as a Hub for Clinical Trials
      • 6.3.2.1 Indian ADMET Testing Market Forecast 2015-2025
    • 6.3.3 South Korea
      • 6.3.3.1 Promoting Local Drug Development in South Korea
      • 6.3.3.2 Growth in the South Korean ADMET Market 2015-2025
  • 6.4 Russia
    • 6.4.1 Changing Drug Development Demands 2010-2015
    • 6.4.2 Russian ADMET Market Forecast 2015-2025
  • 6.5 Brazil: The Largest Market for Drug Development in Latin America 2015-2025
    • 6.5.1 Brazilian ADMET Testing Market Forecast 2015-2025

7. Leading Companies in the ADMET Testing Industry 2014

  • 7.1 Agilent Technologies, Inc.
    • 7.1.1 Agilent Technologies, Inc.: Historical Revenues 2011-2014
    • 7.1.2 Agilent Technologies, Inc. Acquires Cartagenia
  • 7.2 Dassault Systèmes: Acquires Accelrys and forms BIOVIA
    • 7.2.1 Accelrys: Historical Revenues 2011-2013
  • 7.3 Cyprotex
    • 7.3.1 Cyprotex Acquires CeeTox
    • 7.3.2 Cyprotex Historical Revenues, 2010-2014
  • 7.4 Bio-Rad Laboratories, Inc.
    • 7.4.1 Bio-Rad Laboratories, Inc.: Historical Revenues 2011-2014
  • 7.5 Quintiles
    • 7.5.1 Expanding in Developed and Emerging Markets
  • 7.6 Increasing Asian Regional Reach
    • 7.6.1 CMIC Recent and Future Performance Analysis: An Asian Specialist
  • 7.7 Charles River Laboratories Is an Expert in Pre-Clinical Services
  • 7.8 WuXi PharmaTech
    • 7.8.1 WuXi Acquires XenoBiotic Laboratories
    • 7.8.2 WuXi Enters the Clinical Trial Services Market
  • 7.9 Promega Corporation
  • 7.10 Merck KGaA's Acquisition of Sigma Aldrich

8. ADMET Testing Market: Industry Trends 2015-2025

  • 8.1 Strengths and Weaknesses of the ADMET Testing Market
  • 8.2 Opportunities and Threats in the ADMET Testing Market
  • 8.3 ADMET Testing Market: STEP Analysis 2015-2025
    • 8.3.1 Social Factors Affecting ADMET 2015-2025
    • 8.3.2 Drug Developers Must Deal with Ethical Concerns for Animal Testing
  • 8.4 Improving Technology for More Efficient Testing: High-Throughput Evaluation and In Vivo-Like Models
  • 8.5 Economic Considerations for ADMET Testing 2015-2025
    • 8.5.1 Demand for Predictive ADMET Testing
  • 8.6 Political and Regulatory Developments Affecting ADMET Testing 2015-2025
    • 8.6.1 Cutting Red Tape and Other Regulatory Developments in Drug Discovery and Development
    • 8.6.2 Strategic Partnering for Long Term Revenue Growth
    • 8.6.2.1 Sharing Risk Between Pharma and CROs
    • 8.6.3 A Note on CRO Selection
    • 8.6.3.1 Small Pharmaceutical Companies and CROs
    • 8.6.4 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players

9. Research Interviews

  • 9.1 Interview with Dr Roustem Saiakhov, President of MultiCASE, Inc.
    • 9.1.1 Addressing the Challenges in ADMET Testing
    • 9.1.2 Trends in the ADMET Testing Market
  • 9.2 Interview with Yong Huang, PhD, President and CEO of Optivia Biotechnology
    • 9.2.1 ADMET Services at Optivia Biotechnology
    • 9.2.2 Optivia's Partnership with Rhenovia Pharma: CNS Drug Development
    • 9.2.3 Optivia's Partnership with Hurel Corporation: In Vitro-to-In Vivo Correlation
    • 9.2.4 Challenges and Trends in Drug Discovery
    • 9.2.5 Growth of Optivia Biotechnology in the Future?
  • 9.3 Interview with Kristina Runeberg, Site Head of Takara Bio Europe AB
    • 9.3.1 Acquisition of Cellectis AB
    • 9.3.2 Addressing the Challenges in ADMET Testing
    • 9.3.3 Trends in the ADMET Testing Market

10. Conclusions from Our Study

  • 10.1 The World ADMET Testing Market in 2014
    • 10.1.1 A Market Dominated by the Developed Countries
  • 10.2 Strong Growth for the Overall Market 2015-2025
  • 10.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years?
    • 10.3.1 How Can CROs Specialise to Remain Competitive?

List of Tables

  • Table 1.1 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 1.2 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013 and 2014
  • Table 2.1 Pharmacokinetics: Description of ADME
  • Table 2.2 Drug Delivery Routes
  • Table 2.3 Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2015
  • Table 2.4 Founding Members of the ICH
  • Table 3.1 Breakdown of R&D Expenditures by Phase, 2014
  • Table 3.2 CRO Services Revenue by Customer Type, 2014
  • Table 3.3 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 4.1 ADMET Testing Submarket Revenue ($bn) and Market Shares (%), 2014, 2019, and 2025
  • Table 4.2 ADMET Testing Submarket Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 4.3 In Vitro ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 4.4 In Vivo ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 4.5 In Silico ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.1 World ADMET Testing Market by National Market: Revenue ($bn) and Market Share (%), 2014
  • Table 5.2 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.3 ADMET Testing: Market Shares by Country, 2014, 2019 and 2025
  • Table 5.4 US ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.5 EU5 ADMET Testing Market by Country, 2014
  • Table 5.6 EU5 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.7 German ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.8 UK ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.9 French ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.10 Italian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.11 Spanish ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 5.12 Japanese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.1 Leading Emerging Markets for ADMET Testing, 2014
  • Table 6.2 Population Statistics in BRIC Nations, May 2015
  • Table 6.3 English Proficiency in Emerging Markets, 2014
  • Table 6.4 ADMET Testing Market Forecast in Emerging Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.5 Chinese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.6 Indian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.7 South Korean ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.8 Russian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 6.9 Brazilian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025
  • Table 7.1 Selected Companies in the ADMET Testing Industry, 2015
  • Table 7.2 Selected Agilent Technologies MS Products, 2015
  • Table 7.3 Agilent Technologies: Revenue ($bn), AGR (%) and CAGR (%), 2011-2014
  • Table 7.4 Agilent Technologies: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014
  • Table 7.5 Accelrys: Revenue ($bn), AGR (%) and CAGR (%), 2011-2013
  • Table 7.6 Cyprotex ADME & PK Services, 2015
  • Table 7.7 Cyprotex In Vitro Toxicology Services, 2015
  • Table 7.8 Cyprotex In Silico Services, 2015
  • Table 7.9 Cyprotex: Revenue ($bn and £bn), AGR (%) and CAGR (%), 2011-2014
  • Table 7.10 Bio-Rad Laboratories: Revenue ($bn), AGR (%) and CAGR (%), 2011-2014
  • Table 7.11 Quintiles: Service Revenue ($bn), AGR (%) and CAGR (%), 2010-2014
  • Table 7.12 CMIC: CRO Service Revenue ($bn and ¥bn), AGR (%) and CAGR (%), 2011-2014
  • Table 7.13 Charles River Laboratories: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014
  • Table 7.14 WuXi PharmaTech: Revenue ($bn) and CAGR (%) by Sector, 2012-2014
  • Table 8.1 ADMET Testing Market: Strengths and Weaknesses, 2015
  • Table 8.2 ADMET Testing Market: Opportunities and Threats, 2015
  • Table 8.3 ADMET Testing Market: STEP Analysis, 2015
  • Table 10.1 ADMET Testing Market by Sector: Revenue ($bn), CAGR (%) and Market Share (%), 2014, 2019 & 2025

List of Figures

  • Figure 2.1 Drug Design Process
  • Figure 2.2 ADMET Parameters
  • Figure 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014
  • Figure 3.2 CRO Services Revenue by Customer Type, 2014
  • Figure 3.3 ADMET Testing Market: Drivers and Restraints, 2015-2025
  • Figure 3.4 ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 4.1 ADMET Testing Market Revenue ($bn) by Submarket, 2014, 2019 and 2025
  • Figure 4.2 ADMET Testing Submarket Shares (%), 2014
  • Figure 4.3 ADMET Testing Submarket Shares (%), 2019
  • Figure 4.4 ADMET Testing Submarket Shares (%), 2025
  • Figure 4.5 ADMET Testing Market Revenue ($bn) Forecast by Submarket, 2015-2025
  • Figure 4.6 In Vitro ADMET Revenue ($bn) Forecast, 2015-2025
  • Figure 4.7 In Vitro ADMET: Drivers and Restraints, 2015-2025
  • Figure 4.8 In Vivo Submarket Revenue ($bn) Forecast, 2015-2025
  • Figure 4.9 In Vivo ADMET: Drivers and Restraints, 2015-2025
  • Figure 4.10 In Silico Testing Submarket Revenue ($bn) Forecast, 2015-2025
  • Figure 4.11 In Silico Submarket: Drivers and Restraints, 2015-2025
  • Figure 5.1 World ADMET Testing Market by National Market: Market Share (%), 2014
  • Figure 5.2 World ADMET Testing Market by National Market: Market Share (%), 2019
  • Figure 5.3 World ADMET Testing Market by National Market: Market Share (%), 2025
  • Figure 5.4 US ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.5 EU5 ADMET Testing Market Share (%) by Country, 2014
  • Figure 5.6 EU5 ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.7 German ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.8 UK ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.9 French ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.10 Italian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.11 Spanish ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 5.12 Japanese ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.1 Leading Emerging Markets for ADMET Testing by Market Share (%), 2014
  • Figure 6.2 Cost Savings Available for Clinical Trials in Emerging Markets, 2014
  • Figure 6.3 Relative Competence in English in Emerging Markets, 2012
  • Figure 6.4 ADMET Testing: Emerging Market Revenue ($bn) Forecasts, 2015-2025
  • Figure 6.5 Chinese ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.6 Indian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.7 South Korean ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.8 Russian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 6.9 Brazilian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025
  • Figure 7.1 Agilent Technologies: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 7.2 Agilent Technologies: Revenue Share (%) by Sector, 2014
  • Figure 7.3 Accelrys: Revenue ($bn) and AGR (%), 2011-2013
  • Figure 7.4 Cyprotex: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 7.5 Bio-Rad Laboratories: Revenue ($bn) and AGR (%), 2011-2014
  • Figure 7.6 Quintiles: Service Revenue ($bn) and AGR (%), 2010-2014
  • Figure 7.7 CMIC: CRO Service Revenue ($bn) and AGR (%), 2011-2014
  • Figure 7.8 Charles River Laboratories Clinical Trials: Revenue ($bn) by Sector, 2013 and 2014
  • Figure 7.9 WuXi PharmaTech: Revenue ($bn) by Sector, 2012-2014
  • Figure 10.1 ADMET Testing Market Revenue ($bn) by Sector, 2014, 2019 & 2025

Companies Listed

  • AbD Serotec (now part of Bio-Rad Laboratories)
  • ACEA Biosciences
  • Aegis Analytical Corp
  • Agenzia Italiana del Farmaco
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Agilent Technologies
  • Albany Molecular Research
  • Apredica, LLC
  • Associação Brasileira de CROs
  • Association of Clinical Trial Organisations (ACTO) [Russia]
  • AstraZeneca
  • Bayer
  • BD Biosciences
  • Beckman Coulter
  • Bio-Rad Laboratories
  • BIOVIA
  • Boehringer Ingelheim
  • Caliper Life Sciences
  • Cambridge Cell Networks
  • Catalent Pharma Solutions
  • Catalina Health (now part of InVentiv Health)
  • Celerion
  • Cellartis
  • Cellectis AB
  • Cellumen
  • Celsis International
  • Charles River Laboratories
  • ChemSW
  • Chinese Ministry of Commerce
  • Clinipace Worldwide
  • ClinStar (now part of PRA Health Sciences)
  • CMIC Holdings
  • Council for Economic Defense [Brazil]
  • Cromos Pharma
  • CROMSOURCE
  • Cyprotex
  • Department of Health and Human Services [US]
  • EF Education First
  • Entelos Holdings
  • Environmental Protection Agency [US]
  • EPS Holdings, Inc., formerly EPS Corporation
  • European Commission
  • European Medicines Agency (EMA)
  • Fish and Wildlife Service [US]
  • Food and Drug Administration (FDA) [US]
  • Frontage Laboratories
  • GCP ClinPlus
  • I3 Research (now part of InVentiv Health)
  • ICON plc
  • INC Research
  • International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
  • InVentiv Health
  • Harlan Laboratories (now part of Huntingdon Life Sciences)
  • Helmholtz Association
  • Helmholtz Zentrum München (German Research Center for Environmental Health)
  • Hisun Pharmaceuticals
  • Hospital Italiano of Buenos Aires
  • Huntingdon Life Sciences
  • JCL Bioassay Corporation (now part of CMIC)
  • Kendle (now part of INC Research)
  • Kforce Clinical Research (now part of InVentiv Health)
  • Korea Drug Development Fund
  • Korea Food and Drug Administration (KFDA)
  • Korea National Enterprise for Clinical Trials
  • L'Agence Nationale de Sécurité du Médicament (l'ANSM)
  • Les Entreprises du Medicament (LEEM)
  • Life Technologies Corporation
  • LSK
  • Malaysian Biotechnology Corporation
  • Medicines and Healthcare Products Regulatory Agency (MHRA) [UK]
  • Merck & Co.
  • Merck KGaA
  • Mitsubishi Gas Chemical Company, Inc.
  • MultiCASE
  • Nagoya University
  • National Association for Biomedical Research [US]
  • National Cancer Institute (NCI) [US]
  • National Center for Advancing Translational Sciences [US]
  • National Centre for Computational Toxicology [US}
  • National Enterprise for Clinical Trials [South Korea]
  • National Human Genome Research Institute [US]
  • National Institute of Environmental Health Sciences [US]
  • National Institutes of Health (NIH) [US]
  • National Toxicology Program [US]
  • New England Antivivisection Society
  • New York Stock Exchange
  • Noray Bioinformatics
  • Novartis
  • Novotech
  • Oncobiologics
  • Optivia Biotechnology
  • Organovo Holdings, Inc.
  • Parexel
  • PerkinElmer
  • Pharmaron
  • PharmaNet Development Group (now part of InVentiv Health)
  • PRA Health Sciences
  • Prodia Clinical Laboratory
  • Promega Corporation
  • Proteomics
  • ProTrials Research
  • Quintiles
  • ReSearch Pharmaceutical Services (now part of PRA Health Sciences)
  • Rosa & Co
  • Russian Ministry of Public Health
  • Samsung
  • Sekisui Medical Co.
  • Seoul National University Hospital Clinical Trials Center
  • Shanghai Clinical Research Center to
  • ShangPharma
  • Sigma-Aldrich
  • Simulations Plus
  • Sugi Medical Co. (now part of CMIC)
  • Taconic Biosciences
  • Takara Bio Europe AB
  • Takara Bio Inc
  • Tecan Group
  • Thermo Fisher Scientific
  • Tigermed Consulting
  • VelQuest
  • Vialis
  • Vietnam Ministry of Health Administration of Science, Technology and Training (ASST)
  • West Coast Clinical Trials
  • World Health Organization (WHO)
  • WuXi PharmaTech
  • Xceleron
  • XenoBiotic Laboratories
  • XenoTech (now part of Sekisui)
  • Yungjin Pharmaceutical
  • Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd
Back to Top